eprintid: 10162570 rev_number: 7 eprint_status: archive userid: 699 dir: disk0/10/16/25/70 datestamp: 2023-01-05 10:18:26 lastmod: 2023-01-05 10:18:26 status_changed: 2023-01-05 10:18:26 type: article metadata_visibility: show sword_depositor: 699 creators_name: Batzu, Lucia creators_name: Rota, Silvia creators_name: Hye, Abdul creators_name: Heslegrave, Amanda creators_name: Trivedi, Dhaval creators_name: Gibson, Lucy L creators_name: Farrell, Chloe creators_name: Zinzalias, Pavlos creators_name: Rizos, Alexandra creators_name: Zetterberg, Henrik creators_name: Chaudhuri, K Ray creators_name: Aarsland, Dag title: Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease ispublished: pub divisions: UCL divisions: B02 divisions: C07 divisions: D07 divisions: F86 keywords: Science & Technology, Life Sciences & Biomedicine, Neurosciences, Neurosciences & Neurology, NONMOTOR SYMPTOMS SCALE, ALZHEIMERS-DISEASE, TAU, BIOMARKER, IMPAIRMENT, PREDICTION, DIAGNOSIS, ACCURACY, DEMENTIA, DECLINE note: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. abstract: Early identification of cognitive impairment in Parkinson’s disease (PD) has important clinical and research implications. The aim of our study was to investigate the role of plasma tau phosphorylated at amino acid 181 (p-tau181) and plasma neurofilament light chain (NfL) as biomarkers of cognition in PD. Baseline concentrations of plasma p-tau181 and NfL were measured in a cohort of 136 patients with PD and 63 healthy controls (HC). Forty-seven PD patients were followed up for up to 2 years. Cross-sectional and longitudinal associations between baseline plasma biomarkers and cognitive progression were investigated using linear regression and linear mixed effects models. At baseline, plasma p-tau181 concentration was significantly higher in PD subjects compared with HC (p = 0.026). In PD patients, higher plasma NfL was associated with lower MMSE score at baseline, after adjusting for age, sex and education (p = 0.027). Baseline plasma NfL also predicted MMSE decline over time in the PD group (p = 0.020). No significant association between plasma p-tau181 concentration and baseline or longitudinal cognitive performance was found. While the role of p-tau181 as a diagnostic biomarker for PD and its relationship with cognition need further elucidation, plasma NfL may serve as a feasible, non-invasive biomarker of cognitive progression in PD. date: 2022-11-12 date_type: published publisher: NATURE PORTFOLIO official_url: https://doi.org/10.1038/s41531-022-00384-x oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1984934 doi: 10.1038/s41531-022-00384-x medium: Electronic pii: 10.1038/s41531-022-00384-x lyricists_name: Zetterberg, Henrik lyricists_name: Heslegrave, Amanda lyricists_id: HZETT94 lyricists_id: AJHES09 actors_name: Bracey, Alan actors_id: ABBRA90 actors_role: owner funding_acknowledgements: [National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust]; [King's College London]; [Wolfson Foundation]; [Royal Society]; 2018-02532 [Swedish Research Council]; 681712 [European Research Council]; ALFGBG-720931 [Swedish State Support for Clinical Research]; 201809-2016862 [Alzheimer Drug Discovery Foundation (ADDF), USA]; ADSF-21-831376-C [AD Strategic Fund]; ADSF-21-831381-C [AD Strategic Fund]; ADSF-21-831377-C [AD Strategic Fund]; ADSF-21-831376-C [Alzheimer's Association]; ADSF-21-831381-C [Alzheimer's Association]; ADSF-21-831377-C [Alzheimer's Association]; [Olav Thon Foundation]; [Erling-Persson Family Foundation]; [Stiftelsen for Gamla Tjanarinnor]; FO2019-0228 [Hjarnfonden, Sweden]; 860197 [European Union's Horizon 2020 research and innovation program under the Marie Skodowska-Curie grant]; JPND2021-00694 [European Union Joint Program for Neurodegenerative Disorders]; [UK Dementia Research Institute at UCL] full_text_status: public publication: npj Parkinson's Disease volume: 8 article_number: 154 pages: 7 event_location: United States issn: 2373-8057 citation: Batzu, Lucia; Rota, Silvia; Hye, Abdul; Heslegrave, Amanda; Trivedi, Dhaval; Gibson, Lucy L; Farrell, Chloe; ... Aarsland, Dag; + view all <#> Batzu, Lucia; Rota, Silvia; Hye, Abdul; Heslegrave, Amanda; Trivedi, Dhaval; Gibson, Lucy L; Farrell, Chloe; Zinzalias, Pavlos; Rizos, Alexandra; Zetterberg, Henrik; Chaudhuri, K Ray; Aarsland, Dag; - view fewer <#> (2022) Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease. npj Parkinson's Disease , 8 , Article 154. 10.1038/s41531-022-00384-x <https://doi.org/10.1038/s41531-022-00384-x>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10162570/1/s41531-022-00384-x.pdf